Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its participation in two upcoming conferences. The Raymond James SMID Cap Company Showcase will take place on November 13, 2020, featuring one-on-one investor meetings. The Jefferies Virtual London Healthcare Conference is set for November 19, 2020, including a fireside chat at 5:35 PM GMT. Interested investors can contact their representatives for meetings, and a live webcast of the fireside chat will be accessible via the company's website. Ocular Therapeutix develops innovative eye therapies using proprietary technology.
Ocular Therapeutix (NASDAQ:OCUL) announced the acceptance of a permanent Category I Current Procedural Terminology (CPT) code for drug-eluting intracanalicular inserts, including DEXTENZA. This change, effective January 1, 2022, replaces the current Category III CPT code, enhancing reimbursement and coverage across payers. The decision validates DEXTENZA's novel administration method and supports other pipeline products. The CPT code aims to standardize payments for the procedure in both ASC and physician office settings, marking a significant milestone for Ocular Therapeutix and its products.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) has entered a license agreement with AffaMed Therapeutics for the development and commercialization of DEXTENZA® and OTX-TIC in Greater China, South Korea, and ASEAN markets. DEXTENZA is approved for post-surgical ocular inflammation and is being studied for allergic conjunctivitis, while OTX-TIC targets glaucoma. Ocular Therapeutix will receive $12 million upfront and could earn up to $91 million in milestone and support payments along with tiered royalties. The collaboration aims to leverage AffaMed's regional presence in a rapidly growing market, projected at $5 billion in sales.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its third quarter financial results will be reported on November 5, 2020. The company will hold a live conference call at 4:30 p.m. ET to discuss the results and provide a business update. Ocular Therapeutix specializes in innovative eye therapies and has FDA-approved products including DEXTENZA for ocular inflammation post-surgery. Current clinical trials include OTX-TIC, OTX-CSI, and OTX-TKI, with collaborations on extended-delivery formulations for retinal diseases.
Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced a public offering of 7,180,000 shares at $9.75 each, aiming for gross proceeds of approximately $70 million. The underwriters have a 30-day option to purchase an additional 1,077,000 shares. Close date is expected around October 16, 2020. The offering is registered under a previously effective shelf registration statement. This funding may support Ocular Therapeutix's innovative therapies for eye conditions, including DEXTENZA®, its FDA-approved drug.
Ocular Therapeutix, Inc. (Nasdaq: OCUL) has initiated an underwritten public offering of its common stock. The company plans to grant the underwriters an option to purchase up to an additional 15% of the shares sold. All shares in this offering are being sold by the company, with market conditions influencing the completion timeline. The offering is based on a previously effective shelf registration statement with the SEC. Jefferies LLC and Piper Sandler & Co. are the joint book-running managers for the offering.
Ocular Therapeutix (NASDAQ: OCUL) reported preliminary third quarter 2020 net product revenue of $5.8 to $5.9 million, marking a sequential increase of over 250% from Q2. DEXTENZA accounted for $5.3 to $5.4 million of this total, achieving a 280% increase, while ReSure Sealant generated $0.5 million, up 150%. The company noted significant growth in DEXTENZA sales with nearly 10,000 billable units sold, reflecting a recovery in surgical volumes despite COVID-19's impact. Q3 financial results will be detailed on November 5, 2020.
Ocular Therapeutix (NASDAQ:OCUL) has granted a non-statutory stock option for 350,000 shares of common stock to new employee Philip C. Strassburger to incentivize his employment commencement. The option, effective October 5, 2020, has an exercise price of $8.42 per share, matching the closing stock price on that date. It features a ten-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter. This grant complies with Nasdaq Listing Rule 5635(c)(4) and was independently approved by Ocular's Compensation Committee.